Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Replimune Group, Inc. - Common Stock (NQ:REPL)

8.800 +0.380 (+4.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
From Shriram Properties, Havells To Vesuvius: SEBI RA Sees 15% To 30% Upside In These Six Stocks
Via Stocktwits
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
From Pomerantz LLP
Via GlobeNewswire
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
REPL Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against Replimune Group, Inc.
From Robbins LLP
Via GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)
From Bernstein Liebhard LLP
Via GlobeNewswire
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Luminar Technologies, Inc. (NASDAQ: LAZR); Replimune Group, Inc. (NASDAQ: REPL); and RxSight, Inc. (NASDAQ: RXST): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline
From Bleichmar Fonti & Auld LLP
Via Business Wire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL
From The Rosen Law Firm PA
Via GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors
From Kirby McInerney LLP
Via GlobeNewswire
Which stocks are experiencing notable movement on Wednesday?
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
This Centene Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
From Faruqi & Faruqi, LLP
Via Business Wire
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm
From Bleichmar Fonti & Auld LLP
Via Business Wire
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Nasdaq Falls Over 100 Points; Coca-Cola Posts Upbeat Earnings
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action Investigation – REPL
From The Rosen Law Firm, P.A.
Via Business Wire
Gapping stocks in Tuesday's session
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
US Stocks Mixed; General Motors Shares Fall After Q2 Results
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.